68Ga-DOTATATE and 18F-FDG PET/CT in a Rapidly Progressing Lymphoma

68 Ga-DOTATATE PET/CT targeting somatostatin receptors is commonly utilized in the imaging of neuroendocrine tumors. However, other malignancies such as lymphomas (both Hodgkin and non-Hodgkin) also have expression of somatostatin receptors, albeit to a lesser degree compared with the neuroendocrine tumors, and thus can be positive on a 68 Ga-DOTATATE PET/CT. We describe an atypical presentation of an aggressive large B-cell lymphoma mimicking a metastatic neuroendocrine tumor at initial presentation with high somatostatin receptor expression demonstrated on the 68 Ga-DOTATATE PET/CT and a rapidly progressing course on the subsequent 18 F-FDG PET/CT.

Authors

Institutions

Publication Details

Journal
Clinical Nuclear Medicine
Published
2024-10-14
DOI
https://doi.org/10.1097/rlu.0000000000005450
Citations
1
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

68Ga-DOTATATE and 18F-FDG PET/CT in a Rapidly Progressing Lymphoma

Amin Haghighat Jahromi, Richard L. Wahl, Ashwin Singh Parihar
1 citations
Clinical Nuclear Medicine
Neuroendocrine Tumor Research Advances
0.39
article

68Ga-DOTATATE and 18F-FDG PET/CT in a Rapidly Progressing Lymphoma

Amin Haghighat Jahromi, Richard L. Wahl, Ashwin Singh Parihar
article en
1 citations

Abstract

68 Ga-DOTATATE PET/CT targeting somatostatin receptors is commonly utilized in the imaging of neuroendocrine tumors. However, other malignancies such as lymphomas (both Hodgkin and non-Hodgkin) also have expression of somatostatin receptors, albeit to a lesser degree compared with the neuroendocrine tumors, and thus can be positive on a 68 Ga-DOTATATE PET/CT. We describe an atypical presentation of an aggressive large B-cell lymphoma mimicking a metastatic neuroendocrine tumor at initial presentation with high somatostatin receptor expression demonstrated on the 68 Ga-DOTATATE PET/CT and a rapidly progressing course on the subsequent 18 F-FDG PET/CT.

Clinical Nuclear MedicineVol. 50(1)
Mallinckrodt (United States) (US), National Health Insurance Fund (RS)
Good health and well-being
Openalex Percentile: Top 33%
Neuroendocrine Tumor Research Advances
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.